O efeito da BMP-2 sobre as propriedades osteocondutoras do beta-tricálcio fosfato em defeitos de calvária de ratos

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Aplicação do processo sol-gel na produção de recobrimentos de hidroxiapatita sobre ligas a base de Ti empregadas em implantes odontológicos

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Membrana reabsorvível com enxerto ósseo autógeno ou BoneCeramic em rebordos atróficos em implante de titânio: estudo histométrico em cães

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Análise dos indicadores da osteogênese, citotoxicidade e genotoxicidade de substitutos ósseos em osteoblastos-like

Pós-graduação em Biopatologia Bucal - ICT

Análise do processo de reparo de defeitos ósseos críticos em calvária de ratos preenchidos com osso autógeno ou Bone Ceramic: um estudo histométrico e imunoistoquímico

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Análise tomográfica, histológica, histométrica e imunoistoquímica do beta tricálcio fosfato com osso autógeno em aumento do soalho de seio maxilar

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Estudo comparativo do processo de reparo utilizando osso autógeno e beta-tricálcio fosfato em levantamento do assoalho do seio maxilar em humanos: análise tomográfica, histológica, histométrica e imunoistoquímica

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Desenvolvimento de parafuso de interferência bioabsorvível para cirurgia de joelho em PLDL (poli ácido lático) e compósito PLDL + βTCP (beta trifosfato de cálcio)

Pós-graduação em Engenharia Mecânica - FEB

O uso do beta-tricálcio fosfato como substituto ósseo em odontologia

The correction of bone defects is the restoration of lost structures which can be replaced by alloplastic implants or bone grafts. Due to the known disadvantages of removal of autogenous grafts, most researches in dentistry aim to develop alloplastic or non-alloplastic materials able to replace bone without these limitations. Beta-Tricalcium Phosphate (β-TCP) is a synthetic granular bone substitute, biocompatible, osteoconductive, which can be used in the alveolar reconstruction. In this work, we perform a literature review on the β-TCP characteristics and discuss its application in dentistry.

Enamel matrix protein derivative plus synthetic bone substitute for the treatment of mandibular Class II furcation defects: a case series

Objectives: The aim of this study is to report on the treatment of mandibular Class II furcation defects with enamel matrix protein derivative (EMD) combined with a beta TCP/HA (beta-tricalcium phosphate/hydroxyapatite) alloplastic material. Method and Materials: Thirteen patients were selected. All patients were nonsmokers, systemically healthy, and diagnosed with chronic periodontitis; had not taken medications known to interfere with periodontal tissue health and healing; presented one Class II mandibular furcation defect with horizontal probing equal to or greater than 4 mm at buccal site. The clinical parameters evaluated were probing depth (PD), relative gingival margin position (RGMP), relative vertical clinical attachment level (RVCAL), and relative horizontal clinical attachment level (RHCAL). A paired Student t test was used to detect differences between the baseline and 6-month measurements, with the level of significance of .05. Results: After 6 months, the treatment produced a statistically significant reduction in PD and a significant gain in RVCAL and RHCAL, but no observable change in RGMP. RVCAL ranged from 13.77 (+/- 1.31) at baseline to 12.15 (+/- 1.29) after 6 months, with a mean change of -1.62 +/- 1.00 mm (P<.05). RHCAL ranged from 5.54 (+/- 0.75) to 2.92 (+/- 0.92), with a mean change of -2.62 +/- 0.63 mm (P<.05). After 6 months, 76.92% of the patients improved their diagnosis to Class I furcation defects while 23.08% remained as Class II. Conclusion: The present study has shown that positive clinical results may be expected from the combined treatment of Class II furcation defects with EMD and beta TCP/HA, especially considering the gain of horizontal attachment level. Despite this result, controlled clinical studies are needed to confirm our outcomes.

In vitro and in vivo biological behavior of CDHA/OCP/β-TCP scaffold

The biological behavior of a new bioactive material composed of calcium-deficient hydroxyapatite, octacalcium phosphate, and beta-tricalcium phosphate was investigated by in vitro indirect and direct cytotoxicity, cell adhesion and proliferation tests, and by in vivo subcutaneous and bone implantation in rats. The results of the in vitro studies showed that the material is biocompatible and no cytotoxic. Slightly poorer initial cell adhesion and lower cell proliferation than in control was observed, which were attributed to the reactivity and roughness of the material surface, In vivo results showed that the material is biodegradable and bioactive in bone tissue, but only biocompatible and partially biodegradable in soft tissue.

Is bone transplantation the gold standard for repair of alveolar bone defects?

New strategies to fulfill craniofacial bone defects have gained attention in recent years due to the morbidity of autologous bone graft harvesting. We aimed to evaluate the in vivo efficacy of bone tissue engineering strategy using mesenchymal stem cells associated with two matrices (bovine bone mineral and α-tricalcium phosphate), compared to an autologous bone transfer. A total of 28 adult, male, non-immunosuppressed Wistar rats underwent a critical-sized osseous defect of 5 mm diameter in the alveolar region. Animals were divided into five groups. Group 1 (n = 7) defects were repaired with autogenous bone grafts; Group 2 (n = 5) defects were repaired with bovine bone mineral free of cells; Group 3 (n = 5) defects were repaired with bovine bone mineral loaded with mesenchymal stem cells; Group 4 (n = 5) defects were repaired with α-tricalcium phosphate free of cells; and Group 5 (n = 6) defects were repaired with α-tricalcium phosphate loaded with mesenchymal stem cells. Groups 2-5 were compared to Group 1, the reference group. Healing response was evaluated by histomorphometry and computerized tomography. Histomorphometrically, Group 1 showed 60.27% ± 16.13% of bone in the defect. Groups 2 and 3 showed 23.02% ± 8.6% (p = 0.01) and 38.35% ± 19.59% (p = 0.06) of bone in the defect, respectively. Groups 4 and 5 showed 51.48% ± 11.7% (p = 0.30) and 61.80% ± 2.14% (p = 0.88) of bone in the defect, respectively. Animals whose bone defects were repaired with α-tricalcium phosphate and mesenchymal stem cells presented the highest bone volume filling the defects; both were not statistically different from autogenous bone.

Avaliação comparativa do processo de incorporação de bloco sintético bifásico, e do osso autógeno: estudo histológico, histométrico e imunoistoquímico em coelhos

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Use of rhBMP-2 to reconstruct a severely atrophic mandible: a modified approach

This study reports the case of a patient with a severely resorbed mandible who was treated without a bone graft, using short implants, internal rigid fixation, rhBMP-2 and beta-tricalcium phosphate. A 76-year-old woman, with a severely resorbed mandible (less than 3 mm), reported a history of nearly 25 years of complete edentulism and consecutive treatment failures, with total bilateral exposed inferior alveolar nerves and complete bone resorption of the inferior border in some areas. The treatment of choice was the placement of a 2.0 mm thick unilock bone plate (MatrixMandible, Synthes Maxillofacial, Paoli, PA, USA), to reinforce the mandible. Eight short implants with a regular platform (Nobel Biocare, Goteborg, Sweden) were placed: three on the external oblique line on both sides and two on the symphysis. In order to augment mandible height and coat the exposed thread of the anterior implants, rhBMP-2 (Infuse Bone, Meditronic Sofamor Danek, Memphis, TN, USA) and beta-tricalcium phosphate (Cerasorb; Curasan, Kleinostheim, Germany) were used. Four 1.3 mm L miniplates were placed to support the graft. 14 months after surgery, the patient was satisfied and had excellent function without complications.

A phase IIa randomized controlled clinical and histological pilot study evaluating rhGDF-5/?-TCP for periodontal regeneration

The primary objective of this study was to clinically and histologically evaluate periodontal wound healing/regeneration following surgical implantation of recombinant human growth/differentiation factor-5 (rhGDF-5) adsorbed onto a particulate ?-tricalcium phosphate (?-TCP) carrier rhGDF-5/?-TCP into periodontal defects in man.